CoChat
Sign Up
Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access
Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1011923
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
  2. 10.2307/2281868 · DOI · Paper page
  3. Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Cited by

Sorted by citations

Items 801–900 of 1,032

Related

See all

Metadata

Authors
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations
  • Centre Léon Bérard (FR)
  • Centre Hospitalier Universitaire de Reims (FR)
  • Institut Claudius Regaud (FR)
  • Institut Bergonié (FR)
  • Centre Oscar Lambret (FR)
  • Centre Eugène Marquis (FR)
  • Hôpital Ambroise-Paré (FR)
  • Centre Hospitalier de Perpignan (FR)
  • Hôpital de la Croix-Rousse (FR)
  • Centre Hospitalier Universitaire Henri-Mondor (FR)
  • Centre Georges François Leclerc (FR)
  • Université de Rouen Normandie (FR)
  • UniCancer Group (FR)
  • Institut Gustave Roussy (FR)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2011-05-12
Volume
364
Issue
19
Pages
1817-1825
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1011923
OpenAlex
W2151253787
Cited by
7,810
References
37
Citations by year
2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI
150.63
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms
Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review